C Doyon, RG Denis, ED Baraboi, P Samson, J … - Diabetes, 2006 - Am Diabetes Assoc The effects of the cannabinoid-1 receptor (CB 1 ) antagonist rimonabant on
energy metabolism and fasting-induced hypothalamic-pituitary-adrenal (HPA) axis
and neuronal activation were investigated. Lean and obese Zucker rats were ... Cited by 21 - Related articles - BL Direct - All 5 versions
- ►endojournals.org AW Herling, S Kilp, R Elvert, G Haschke, W … - Endocrinology, 2008 - Endocrine Soc The CB1 receptor antagonist, rimonabant, affects the endocannabinoid system and
causes a sustained reduction in body weight (BW) despite the transient nature of
the reduction in food intake. Therefore, in a multiple-dose study, female ... Cited by 15 - Related articles - BL Direct - All 4 versions
- ►physiology.org AW Herling, M Gossel, G Haschke, S … - American Journal of Physiology- Endocrinology And …, 2007 - Am Physiological Soc The objective of the present study was to investigate in fed Wistar rats whether
the cannabinoid-1 (CB1) receptor antagonist AVE1625 causes primary effects on
metabolic blood and tissue parameters as well as metabolic rate, which are ... Cited by 18 - Related articles - BL Direct - All 4 versions
AW Herling, S Kilp, HP Juretschke, C … - International Journal of Obesity, 2008 - nature.com Candy-diet increased body weight, which was predominantly due to the increased
total fat mass with predominance of visceral fat accumulation. Treatment with
rimonabant fully reversed the weight gain and fat deposition in the ... Cited by 3 - Related articles - All 3 versions
I Kunz, MK Meier, A Bourson, M Fisseha, W … - International journal of obesity, 2008 - nature.com Results: Compared with vehicle-treated rats, rats administered 3 and 10 mg kg -
1 rimonabant showed an 18 and 49% increase in O 2 consumption, respectively
after 3 h. A second dose of rimonabant administered 9–14.5 h after the ... Cited by 6 - Related articles - All 5 versions
ZD Thornton-Jones, GA Kennett, KR Benwell, … - Pharmacology Biochemistry and Behavior, 2006 - Elsevier The cannabinoid CB 1 receptor inverse agonist rimonabant induces hypophagia and
body weight loss. Reduced body weight may potentially be due to decreased food
intake or to direct metabolic effects of drug administration on energy ... Cited by 19 - Related articles - All 4 versions
- ►diabetesjournals.org L Tedesco, A Valerio, C Cervino, A Cardile, C … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—SR141716 treatment increased eNOS expression in cultured white
adipocytes. Moreover, SR141716 increased mitochondrial DNA amount, mRNA levels
of genes involved in mitochondrial biogenesis, and mitochondrial mass and ... Cited by 11 - Related articles - All 4 versions
AE Rigamonti, C Giordani, SM Bonomo, SG … - European journal of pharmacology, 2006 - Elsevier In the acute experiments, each dose of SR141716 (1, 5 and 10 mg/kg ip) reduced
food intake with respect to vehicle-treated rats, whereas hexarelin (160 μg/kg
sc) markedly stimulated feeding. All doses of SR141716 were capable to ... Cited by 12 - Related articles - All 4 versions
PV Piazza, M Lafontan, J Girard - Diabetes and Metabolism, 2007 - Elsevier The discovery of the endocannabinoid system (ECS) has raised a large interest in
the scientific community providing us with a strikingly long list of apparently
independent multi organ effects. As a result, in most reviews on this issue ... Cited by 3 - Related articles - BL Direct - All 3 versions
SP Vickers, LJ Webster, A Wyatt, CT Dourish, … - Psychopharmacology, 2003 - Springer Abstract Rationale: The selective CB 1 receptor antago- nist, SR 141716, has
been demonstrated to reduce food consumption in a range of animal species.
Objective: To assess the effect of chronic administration of SR 141716 on ... Cited by 105 - Related articles - BL Direct - All 4 versions
